|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of lung
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although uncommon, BRAF mutations in human lung cancers may identify a subset of tumors sensitive to targeted therapy.
|
12460918 |
2002 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although a few Caucasian lung cancer patients harbored BRAF mutations, there have been no reports about the BRAF mutation in Japanese patients with lung cancer.
|
16376942 |
2006 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data, together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer, suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping.
|
19010912 |
2008 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.
|
21463141 |
2011 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Consistent with earlier reports, our results show that KRAS and BRAF mutation frequencies in colorectal cancer were 44.3% and 13.0%, respectively, while EGFR mutations were detected in 11.1% of the lung cancer specimens.
|
21943394 |
2011 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
22649091 |
2012 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers.
|
22407457 |
2012 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
|
22773810 |
2012 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas.
|
22012135 |
2012 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Colorectal and lung cancers associated with the BRAF V600E mutation often demonstrated mucinous morphology.
|
23370429 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are found in 3% of human non-small cell lung cancers.
|
23825589 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This interesting phenomenon (often called "drug dependency" or "drug addiction") is exemplified in preclinical acquired resistance models of BRAF-mutated melanoma treated with vemurafenib and EGFR-mutated lung cancer treated with EGFR tyrosine kinase inhibitors.
|
23900694 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We evaluated a sensitive liquidchip platform for detecting EGFR, KRAS (alias Ki-ras), proto-oncogene B-Raf, and phosphatidylinositol 3-kinase CA mutations in plasma samples, which were highly correlated with matched tumor tissues from 86 patients with advanced non-small-cell lung cancers.
|
23988622 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequency of BRAF mutations in lung cancer was low in an Asian cohort.
|
24297085 |
2014 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
|
24550319 |
2014 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Nineteen percent of patients with early-stage BRAF mutant lung cancers developed second primary lung cancers harboring KRAS mutations.
|
25436800 |
2014 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mutations (p.D594G [18%], p.V600E [14%], and p.G469A [9%]).
|
26386083 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Jointly, our results suggest a potential role of the novel BRAF fusion in lung cancer development and therapy.
|
25985019 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutants with impaired or unknown kinase activity as well as concomitant kinase-impaired BRAF mutations and RAS mutations were detected in lung cancers, colorectal cancers and melanomas.
|
26498038 |
2015 |